133 Effects of Cyclospasmol Upon Sensory Parameters in Patients Recovering from Cerebrovascular Accidents L. Sourander, M.D. and C. B. Blakemore, PH.D. TURKU, FINLAND From the University of Turku and City Hospital of Turku, Finland, and Cane Hill Hospital, Coulsdon, Surrey, England. The literature on the therapeutic value of cyclandelate (Cyclospasmol) in the treatment of mental impairment associated with arteriosclerotic dementia is now quite extensive and stretches over at least the past decade. More recently, attempts have been made to evaluate the usefulness of this drug in recovery from other conditions involving cerebral impairment, such as the effects of traumatic brain injury and recovery from cerebrovascular accidents. This report describes two studies carried out to assess the therapeutic response to cyclandelate by patients recovering from cerebrovascular accidents. The aim of the first study was to establish the effectiveness of the drug on certain sensory-motor and perceptual abilities in the poststroke patient, and the second investigation aimed at establishing an optimal dosage of the drug in the treat- ment of these clinically relevant variables. Study I ... Subjects. Fifty-two geriatric patients, 32 women and 20 men with a mean age of 74 years, were selected from the wards of the Department of Internal Medicine, City Hospital, Turku, Finland, and were included in this study. Forty of these patients completed the study and generated analyzable data. Of the 12 patients who did not complete the study, 3 died, 2 deteriorated physically to the point of being unable to participate, 2 were discharged from the hospital, and 5 did not complete all the tests required by the design of the investigation. Those patients participating in this study comprised members of two dis- tinct, clinically diagnosable groups, which will be referred to as group 1 and group 2. Group 1 patients had each suffered a cerebrovascular accident and were kept in the hospital because they only partially recovered normal functions after surviving the stroke. All group 1 patients had suffered their stroke at least 2